Stay current with the latest sickle cell research, regulatory updates, and guidelines.
To evaluate whether palmitoylethanolamide (PEA), a non-intoxicating lipid mediator related to cannabinoid signaling, could reduce pain hypersensitivity and inflammatory activity in sickle cell disease (SCD).
To evaluate whether a structured Project ECHO virtual learning series could improve healthcare professionals’ knowledge and confidence in facilitating transition from pediatric to adult care for patients with sickle cell...
To evaluate the efficacy and safety of etavopivat, a selective activator of red blood cell pyruvate kinase, in patients with sickle cell disease (SCD). Etavopivat improves red cell energy metabolism...
To evaluate whether a structured Project ECHO virtual learning series could improve healthcare professionals’ knowledge and confidence in facilitating transition from pediatric to adult care for patients with sickle cell...
To evaluate soluble C5b-9 (sC5b-9), a marker of terminal complement activation, as a biomarker for hemolysis-associated complications in sickle cell disease (SCD).
To investigate how placental pathology contributes to adverse pregnancy outcomes in sickle cell disease (SCD).
To evaluate whether non-genotoxic antibody-drug conjugate (ADC) conditioning can support donor hematopoietic engraftment in a murine sickle cell disease (SCD) transplant model.
To assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and biologic activity of pociredir in patients with SCD, including effects on fetal hemoglobin (HbF) and hemolysis.
To evaluate breast cancer screening utilization and mammographic characteristics among women living with sickle cell disease (SCD).
To explore the relationship between cerebral blood flow (CBF) and pain sensitivity in adults with sickle cell disease (SCD).